

Table 3: Symptoms scores and quality of life scales

	RT-B n=19	IB n=23	<i>P value</i>
Severity score			
FACED ^a	2 ± 1	2 ± 1	0.828
E-FACED ^b	2 ± 2	3 ± 2	0.763
Symptoms score			
CASA-Q			
Cough symptom	71 ± 23	41 ± 24	0.029
Cough impact	75 ± 28	48 ± 28	0.408
Sputum symptom	73 ± 25	52 ± 28	0.258
Sputum impact	83 ± 19	61 ± 28	0.453
HAD			
Anxiety (mean)	7 ± 5	7 ± 5	0.814
Depression (mean)	5 ± 4	6 ± 4	0.480
Quality of life scales			
SGRQ			
Total score	34 ± 27	45 ± 25	0.425
MOS SF-36			
Global physical score	35 ± 12	37 ± 14	0.351
Global mental score	23 ± 24	30 ± 17	0.351

Data are expressed as mean ± standard deviation.

IB: patients with idiopathic bronchiectasis, RT-B: patients with renal transplantation and bronchiectasis,

CASA-Q : *Cough And Sputum Assessment Questionnaire* score assessing impact of cough and sputum production on daily activities, ranging from 0 to 100, with the highest score corresponding to a better quality of life, HAD: *Hospital Anxiety and Depression Scale (HAD)*: A score between 0–7 for anxiety or depression domain meant no trouble, 8–10 suspected troubles, 11–21 confirmed troubles, SGQR: *St George's respiratory questionnaire (SGRQ)* assessing symptoms and impact on daily activities with a score ranging from 0 to 100, that indicates the maximum impairment of quality of life, MOS SF-36: *Medical Outcome Study Short Form 36 health survey*, a multidimensional generic scale evaluating health status regardless of causal disease, sex, age and treatment. A Physical Composite Score and a Mental Composite Score was calculated. A score of 100 indicates no impairment of quality of life (24).

^aFACED score incorporates five variables: forced expiratory volume in 1 second (FEV₁) % predicted, age, chronic colonization by *P. aeruginosa*, extension of bronchiectasis by radiological assessment and dyspnea.

^b E-FACED score also includes the occurrence of exacerbations in the previous year.